Targeted therapy consisting in tyrosine kinase inhibitors (TKIs) has significantly improved the life expectancy of leukemia patients; however, resistance to TKIs remains a major clinical challenge. Most patients eventually relapse due to a variety of resistance mechanisms that allow a subpopulation of cancer cells to survive the treatment. For these patients the treatment options are very limited. There is an urgent need for the identification of novel therapies and drug resistance mechanisms.


In this project we aim to identify novel therapies that prevent relapse in patients after TKI treatments. By using an innovative chemical-genetic screen based on CRISPR-Cas9 technology, we have identified potential target proteins involved in TKI resistance mechanisms. We hypothesize that an effective treatment to overcome drug resistance could be targeting these proteins, identified in the screen, in combination with TKI treatment. In this project, the student will evaluate the inhibitory effect of these new identified combinations on cancer cell survival by performing in vitro, ex vivo and in vivo assays. We also want to characterize the molecular mechanisms that mediate TKI resistance.



What we offer the student


  • Experience with the basic and cutting edge Cancer Molecular Medicine.
  • Experience in molecular biology and biochemistry methods: CRISPR-Cas9 technology,

  ChIP- and RT-q-PCR, ChIP- and RNA-seq, immunofluorescence, flow cytometry, Western

  blotting, PCR, cloning, etc

  • Training in transferrable skills: presentations, writing, project planning
  • You get to be part of an international research team with researchers at different stages of

   their careers

  • Frequent opportunities to get input on your data (weekly lab meetings) and to get updated on

  the most recent advances in our field of interest (“journal club” presentations)

  • We have an ambitious environment where team members share their expertise to help each

  other get better!


Our research group

The Cancer Molecular Medicine research group is led by Jorrit Enserink and consists of 12 members from 7 different countries. One of our research areas is leukaemia and the development of new therapies for AML patients, where we have established a personalised medicine drug screening platform. The group is a young and dynamic environment and has long experience in supervision of Masters and PhD students. Our group is part of the Department for Molecular Cell Biology at the Institute for Cancer Research (Radiumhospitalet) where we share facilities, reagents and expertise with other groups in both our department and around the hospital.


Supervisors for this project:

Jorrit Enserink and Carmen Herrera

Publisert 12. feb. 2019 12:26 - Sist endret 5. aug. 2019 13:26

Omfang (studiepoeng)